Melanoma Clinical Trial
Minimally Invasive Groin Dissection for Melanoma
Summary
The purpose of this this study is to determine if a structured educational training program is successful in teaching surgeons a new operative technique. It will then be determined if this new operative technique is safe.
Full Description
This study is a multi-center, Phase 1 clinical trial to determine the safety and feasibility of minimally invasive inguinal lymph node dissection for patients with melanoma. Licensed surgeons who have undergone special training, including a course at the Mayo Clinic Rochester in minimally invasive lymph node dissection (MILND) will perform the new procedure at their home institutions. The study will characterize the learning curve of MILND in the clinical setting, and evaluate the safety of the new operative technique.
The hypotheses for this study are: 1) minimally invasive groin dissection is a safe procedure. 2) a structured educational training program is a feasible and effective method to train practicing surgeons in this novel procedure and 3) pre-course generic laparoscopic technical skills correlate with minimally invasive superficial groin dissection performance in a clinical setting, including operative oncologic standards and safety metrics.
Eligibility Criteria
Inclusion criteria:
Malignant melanoma present in an inguinal nodal basin requiring superficial inguinal lymph node dissection.
Plan for superficial inguinal dissection alone or combined superficial inguinal and deep pelvic node dissection is acceptable.
Clinical or radiographic evidence of superficial inguinal lymph node disease or a prior positive single lymph node biopsy of the superficial inguinal basin as an indication for superficial inguinal lymph node disease is acceptable.
Patients must be Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and be healthy enough to undergo a general anesthetic (no epidural or spinal anesthetics).
Female patients of child bearing age must have a negative pregnancy test, be surgically sterile or post-menopausal greater than 1 year.
Patients must be able to return to surgical facility for 30 and/or 90 day (+/- 20 days) for follow-up appointment.
Exclusion Criteria:
Prior ipsilateral superficial inguinal lymph node dissection
Invasion or ulceration of inguinal nodal disease into the overlying skin
Prior radiation therapy to the same regional nodal basin.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 11 Locations for this study
Scottsdale Arizona, 85259, United States
Santa Monica California, 90404, United States
Jacksonville Florida, 32224, United States
Tampa Florida, 33612, United States
Chicago Illinois, 60611, United States
New York New York, 10065, United States
Durham North Carolina, 27710, United States
Cleveland Ohio, 44109, United States
Columbus Ohio, 43210, United States
Philadelphia Pennsylvania, 19111, United States
Madison Wisconsin, 53792, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.